General Information of Drug (ID: DM1UIOA)

Drug Name
XB-947 Drug Info
Synonyms XR-469R; (+)-2(R)-[4-(7-Chloroquinoxalin-2-yloxy)phenoxy]propionic acid sodium salt; (R)-(+)-XK-469
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
157156
CAS Number
CAS 78104-71-9
TTD Drug ID
DM1UIOA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexrazoxane DMD7X1O Breast cancer 2C60-2C65 Approved [3]
XK-469 DMVYO41 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
A-62176 DM4WT7Z N. A. N. A. Terminated [5]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [6]
3'-THIO-THYMIDINE-5'-PHOSPHATE DM5SM8X Discovery agent N.A. Investigative [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II beta (TOP2B) TT4NVEM TOP2B_HUMAN Modulator [2]

References

1 A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 August; 44(12): 1684-1692.
2 XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173.
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32.
5 Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8.
6 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.